A randomised, placebo-controlled, double-blind trial of the antidepressant efficacy of a novel CNS-penetrant P2X7 receptor antagonist, JNJ-54175446, in people with major depressive disorder, an inc...
This historical record does not confirm current site availability.
Understand this study
What is this study about?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
Who could participate?
This study is for people with depression. Other eligibility criteria apply.
- Listed locations
- United Kingdom
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
This is historical registry information. What is the current study status and protocol?
Things to check before joining
- Recruitment status
- Recruitment unclear
- Enrollment listed in the registry
- 142
- Sponsor
- Cambridgeshire and Peterborough NHS Foundation Trust and University of Cambridge
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United Kingdom
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2018-001884-21
- Official title
Show the full official title
A randomised, placebo-controlled, double-blind trial of the antidepressant efficacy of a novel CNS-penetrant P2X7 receptor antagonist, JNJ-54175446, in people with major depressive disorder, an inc...
Recruitment & locations
United Kingdom
Registry details
- United Kingdom — GB - no longer in EU/EEA
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Cambridgeshire and Peterborough NHS Foundation Trust and University of Cambridge, a university.
Who can participate?
This study is for people with depression. Other eligibility criteria apply.
